Pharmacology and Pharmacogenetics of Chemotherapeutic Agents

REFERENCES

• Bordet R., Gautier S., Le Louet H., et al. Analysis of the direct cost of adverse drug reactions in hospitalized patients. Eur J Clin Pharmacol 2001; 56: 935–941
   PubMed Web of Science ®Google Scholar
• Evans W. E., Relling M. V. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 1999; 286: 487–491
   PubMed Web of Science ®Google Scholar
• Jeffrey S., Ross M. D., David P., et al. Pharmacogenomics. Adv Anat Pathol 2004; 11: 211–220
   PubMed Web of Science ®Google Scholar
• Lazarou J., Pomeranz B. H., Corey P. N. Incidence of adverse drug reactions in hospitalized patients—a meta-analysis of prospective studies. JAMA 1998; 279: 1200–1205
   PubMed Web of Science ®Google Scholar
• Johnson J. A., Bootman J. L. Drug-related morbidity and mortality. A cost-of-illness model. Arch Intern Med 1995; 155: 1949–1956
   PubMed Web of Science ®Google Scholar
• Egorin M., Echo D. V., Olman E., et al. Prospective validation of a pharmacologically based dosing scheme for the cisdiamminedichloroplatinum (II) analogue diamminecylobutane dicarboxylato platinum. Cancer Res 1985; 45: 6502
   PubMedGoogle Scholar
• Calvert A., Newell D., Gumbrell L., et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989; 7: 1748
   PubMed Web of Science ®Google Scholar
• Lichtman S. M., Hollis D., Miller A. A., et al. Prospective evaluation of the relationship of patient age and paclitaxel clinical pharmacology: Cancer and Leukemia Group B (CALGB 9762). J Clin Oncol 2006; 24: 1846–1851
   PubMed Web of Science ®Google Scholar
• Sachidanadam R., Weissman D., Schmidt S. C., et al. A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms. Nature 2001; 409: 928–933
   PubMed Web of Science ®Google Scholar
• Evans D. A., Manley K. A., McKusch V. A., et al. Genetic control of isoniazid metabolism in man. Br Med J 1960; 2: 485–491
   PubMed Web of Science ®Google Scholar
• Knight R. A., Selin M. J., Harris H. W., et al. Genetic factors influencing isoniazid blood levels in humans. Trans Conf Chemother Tuberc 1959; 8: 52–56
   Google Scholar
• Evans D. A. Survey of human acetylator polymorphism in spontaneous disorders. J Med Genet 1984; 21: 243–253
   PubMed Web of Science ®Google Scholar
• Ratain M. J., Mick R., Berezin F., et al. Paradoxical relationship between acetylator phenotype and amonafide toxicity. Clin Pharmacol Ther 1991; 50: 573–579
   PubMed Web of Science ®Google Scholar
• Pui C.-H., Evans W. E. Acute lymphoblastic leukemia. New Engl J Med 1998; 339: 605–615
   PubMed Web of Science ®Google Scholar
• Krynetski E. Y., Tai H. L., Yates C. R., et al. Genetic polymorphisms of thiopurine S-methyltransferase: clinical importance and molecular mechanisms. Pharmacogenetics 1996; 6: 279–290
   PubMedGoogle Scholar
• McLeod H. L., Coulthard S., Thomas A. E., et al. Analysis of thiopurine methyltransferase variant alleles in childhood acute lymphoblastic leukemia. Br J Hematol 1999; 105: 696–700
   PubMed Web of Science ®Google Scholar
• Pui C.-H., Relling M. V., Cheng Cheng, et al. Thiopurine methyltransferase in acute lymphoblastic leukemia. Blood 2006; 107: 843–844
   PubMed Web of Science ®Google Scholar
• Molloy A. M., Daly S., Mills J. L., et al. Thermolabile variant of 5,10-methylenetetrahydrofolate reductase associated with low red-cell folates: implications for folate intake recommendations. Lancet 1997; 349: 1591–1593
   PubMed Web of Science ®Google Scholar
• Franco R. F., Simoes B. P., Tone L. G., et al. The methylenetetrahydrofolate reductase C677T gene polymorphism decreases the risk of childhood acute lymphocytic leukemia. Br J Haematol 2001; 115: 616–618
   PubMed Web of Science ®Google Scholar
• Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials. Lancet 2005; 365: 1687–1717
   PubMed Web of Science ®Google Scholar
• Lonning P. E., Lien E. A., Lundgren S., et al. Clinical pharmacokinetics of endocrine agents used in advanced breast cancer. Clin Pharmacokinet 1992; 22: 327–358
   PubMed Web of Science ®Google Scholar
• Stearns V., Johnson M. D., Rae J. M., et al. Active tamoxifen metabolite plasma concentrations after co administration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst 2003; 95: 1758–1764
   PubMed Web of Science ®Google Scholar
• Osborne C. K. Tamoxifen in the treatment of breast cancer. N Engl J Med 1998; 339: 1609–1618
   PubMed Web of Science ®Google Scholar
• Desta Z., Ward B. A., Soukhova N. V., et al. Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D. J Pharmacol Exp Ther 2004; 310: 1062–1075
   PubMed Web of Science ®Google Scholar
• Jin Y., Desta Z., Stearns V., et al. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst 2005; 97: 30–39
   PubMed Web of Science ®Google Scholar
• Goetz M. P., Rae J. M., Suman V. J., et al. Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol 2005; 23: 9312–9318
   PubMed Web of Science ®Google Scholar
• Iyer L., King C. D., Whitington P. F., et al. Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J Clin Invest 1998; 101: 847–854
   Google Scholar
• Heidelberger C., Chaudhuri N. K., Danneberg P., et al. Fluorinated pyrimidines, a new class of tumor-inhibitory compounds. Nature 1957; 179: 663–666
   PubMed Web of Science ®Google Scholar
• Etienne M. C., Lagrange J. L., Dassonville O., et al. Population study of dihydropyrimidine dehydrogenase in cancer patients. J Clin Oncol 1994; 12: 2248–2253
   PubMed Web of Science ®Google Scholar
• McLeod H. L., Collie-Duguid E. S., Vreken P., et al. Nomenclature for human DPYD alleles. Pharmacogenetics 1998; 8: 455–459
   PubMedGoogle Scholar
• Lu A., Zhang R., Diasio R. B. Dihydropyrimadine dehydrogenase activity in human peripheral blood mononuclear cells and liver: population characteristics, newly identified deficient patients, and clinical implication in 5-fluorouracil chemotherapy. Cancer Res 1993; 53: 5433–5438
   PubMed Web of Science ®Google Scholar
• Raida M., Schwabe W., Hausler P., et al. Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5′-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)-related toxicity compared with controls. Clin Cancer Res 2001; 7: 2832–2839
   PubMed Web of Science ®Google Scholar
• Grem J. L. 5-Fluorouracil: forty-plus and still ticking. A review of its preclinical and clinical development. Invest New Drugs 2000; 18: 299–313
   PubMed Web of Science ®Google Scholar
• Leichman C. G., Lenz H. J., Leichman L., et al. Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin. J Clin Oncol 1997; 15: 3223–3229
   PubMed Web of Science ®Google Scholar
• Horie N., Aiba H., Oguro K., et al. Functional analysis and DNA polymorphism of the tandemly repeated sequences in the 5′-terminal regulatory region of the human gene for thymidylate synthase. Cell Struct Funct 1995; 20: 191–197
   PubMed Web of Science ®Google Scholar
• Marsh S., Mckay J. A., Cassidy J., Mcleod H. L. Polymorphism in the thymidylate synthase promoter enhancer region in colorectal cancer. Int J Oncol 2001; 19: 383–386
   PubMed Web of Science ®Google Scholar
• Flochart D. A. Pharmacogenomics in the endocrine treatment of breast cancer. San Antonio Breast Cancer Symposium, MINI Symposium 4 2005
   Google Scholar